Tak W. Mak, OC, FRS, Chairman
Dr. Mak is Director of The Campbell Family Institute for Breast Cancer Research, and Professor, University of Toronto, Departments of Medical Biophysics and Immunology. He served as Vice President of Research, Amgen, Inc. and Director of the Amgen Research Institute (Toronto) from 1993 to 2002. Dr. Mak is internationally recognized for his breakthrough discoveries in cancer genetics, immunology, molecular biology and virology. These discoveries include locating, isolating and cloning the T cell receptor and creating genetically-engineered mice to increase the understanding of the human immune system, apoptosis and tumorigenesis. He holds numerous patents and has published over 650 articles, many in high-impact scientific journals around the world.

Dr. Mak has received several awards including the Sloan Prize of the General Motors Cancer Foundation, King Faisal International Prize for Medicine, Novartis Prize in Immunology, Gairdner International Award, E.W.R. Steacie Award (NSERC), Ayerst Award (Canadian Biochemical Society), Stacie Prize (Stacie Trust Foundation), Robert Noble Prize (NCIC), Killam Prize in Health Sciences (Canada Council for the Arts) and the Order of Canada. In March 2004, he received the 2004 Paul Ehrlich and Ludwig Darmstaedter Preis in Germany. He is a member of the National Academy of Sciences (USA), the Royal Society of London, and the Royal Society of Canada.

S. Gail Eckhardt, MD
Dr. Eckhardt is Professor of Medicine at the University of Colorado Denver in Aurora, Colorado. She also serves as Director of the Developmental Therapeutics Program at the University of Colorado Cancer Center, and is the Division Head of Medical Oncology. Dr. Eckhardt oversees the Clinical Phase I Program and the Colorectal Cancer Translational Research Laboratory. She earned her medical degree from the University of Texas Medical Branch in Galveston, Texas. Dr. Eckhardt completed her internship and residency in internal medicine at the University of Virginia Medical Center in Charlottesville. Her postgraduate training also included a research fellowship at the Division of Experimental and Molecular Medicine, Scripps Clinic and Research Foundation, La Jolla, California; a medical oncology fellowship at the Division of Hematology/Oncology, University of California, San Diego Hospitals, and a research fellowship, Departments of Medicine and Biology, University of California, San Diego, School of Medicine, La Jolla.

Dr. Eckhardt has served on numerous committees/study sections, including the ASCO Board of Directors, ASCO Molecular Oncology Task Force, the EORTC Early Clinical Trials Review Panel, and the NCI Drug Development Group. She was also Chair of the ASCO Program Committee in 2003, and Co-Chair of the first ASCO/SSO/ASTRO/AGA GI Symposium in 2004. In addition, Dr. Eckhardt has been an Associate Editor of Clinical Cancer Research, JCO, and Investigational New Drugs. Furthermore, she is the Principal Investigator on several peer-reviewed grants involving early clinical trials and colorectal cancer research and has conducted numerous phase I and II clinical trials. She has published over 90 manuscripts and serves on numerous advisory boards. Dr. Eckhardt is currently serving on the the FDA Oncology Drugs Advisory Committee and the Gastrointestinal Steering Committee of the NCI.

Michael E. Weinblatt, MD
Dr. Weinblatt is Co-Director of Clinical Rheumatology at the Brigham and Women’s Hospital and is currently the John R. and Eileen K. Riedman Professor of Medicine at Harvard Medical School. He specializes in therapeutic interventions in rheumatoid arthritis. Dr. Weinblatt is co-editor of the textbook, Treatment of Rheumatic Diseases, the textbook, Rheumatology 3rd and 4th edition, and author of the Arthritis Action Program. He co-received the Arthritis Foundation Virginia P. Engalitcheff Award for Impact on Quality of Life and the Carol Nachman Prize (2005) for his work on the development of methotrexate as a therapy for rheumatoid arthritis. Dr. Weinblatt served as an Associate Editor of Arthritis and Rheumatism and currently sits on multiple editorial boards including the Journal of Rheumatology. He was a member of the Rheumatology Subspecialty Board of the American Board of Internal Medicine. Dr. Weinblatt has also served as the President of the American College of Rheumatology (ACR).

Hans Wigzell, MD, PhD
Professor Wigzell served as the President of the Karolinska Institute in Stockholm, Sweden from 1995 to 2003, and has served as Professor of Immunology at Karolinska and Uppsala University. In 1990, Dr. Wigzell was elected Chairman of the European Union (EU) Concerted Research Programme into AIDS vaccination, EVA. He served as the Chairman of the Nobel Committee at Karolinska Institute 1990-1992. In 1991, Dr. Wigzell was appointed Director of the Swedish Institute for Infectious Disease Control. He served as Chief Scientific Advisor to the Swedish Government from1999-2007. Dr. Wigzell graduated from the Karolinska Institute as Doctor of Medicine (M.D. and also as a Ph.D.). He is a member of several national academies of sciences and has published more than 700 articles in international peer reviewed journals.

Carolyn F. Sidor, MD, MBA
Dr. Sidor is Vice President and Chief Medical Officer of EntreMed. She joined the Company in 2001 as Vice President, Clinical & Regulatory Affairs and was appointed Chief Medical Officer in September 2004. Dr. Sidor is a board-certified hematologist/medical oncologist. From 1993 until 2001, she held various leadership positions at Cato Research Ltd., a prominent Clinical Research Organization (CRO), including Vice President, Scientific and Medical Development; Medical Director; Senior Clinical Research Physician; and Project Director. Dr. Sidor also holds a clinical staff appointment in the Department of Medicine at the University of North Carolina at Chapel Hill. From 1985 to 1993, She was Associate Professor and Physician at Philadelphia’s Lankenau Hospital, Department of Medicine. Dr. Sidor earned her M.D. degree from Thomas Jefferson University School of Medicine and her M.B.A. degree from the University of Delaware.

Mark R. Bray, MSc, PhD
Dr. Mark R. Bray is Vice President, Research of EntreMed. He joined the Company in January 2006 as Senior Director, Research and in November 2007, Dr. Bray was promoted to Vice President, Research. Dr. Bray has spent his scientific career working towards the development of drugs for oncology and inflammatory diseases. Dr. Bray joined EntreMed in 2006 following the acquisition of Miikana Therapeutics, Inc., a biopharmaceutical company co-founded by Dr. Bray and others, which was focused on the development of targeted therapeutics for the treatment of cancer. Prior to the founding of Miikana in November 2002, Dr. Bray was Head of Quantitative Biology at the Amgen Research Institute in Toronto, Canada, and acted as Project Team Leader for multiple drug discovery efforts at Amgen, Thousand Oaks, CA.

Dr. Bray obtained his M.Sc. and Ph.D. degrees from the University of Guelph, followed by postdoctoral fellowships at the University of British Columbia and the Ontario Cancer Institute.